Market revenue in 2023 | USD 29.2 million |
Market revenue in 2030 | USD 43.5 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.7% in 2023. Horizon Databook has segmented the Argentina in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
The Ministry of Health and the National Administration of Drugs, Food and Medical Devices (ANMAT) are making numerous efforts to increase clinical research & trial activities in Argentina. Moreover, ANMAT, in 2017, reduced the timelines for approval of clinical trials from 160 to 70 business days, modifying the Provision Nº 6677/10 that governs clinical research in Argentina. This is expected to propel the in vivo CRO market during the forecast period.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account